Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Dr Tarantino on the Expanding Role of T-DXd in HER2+ Breast Cancer

May 13th 2025

Paolo Tarantino, MD, discusses the expanding role of T-DXd in HER2-positive breast cancer.

BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer

May 13th 2025

Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.

CX-2051 Demonstrates Preliminary Activity in Heavily Pretreated Advanced Colorectal Cancer

May 13th 2025

CX-2051 elicited an overall response rate of 28% with manageable safety in heavily pretreated colorectal cancer.

Dr Sobh on Ongoing Investigations of NSD2 in Modulating Immune Surveillance in Myeloma

May 12th 2025

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

Dr Garcia on the Effect of the Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in in PSMA+ mCRPC

May 12th 2025

Jorge A. Garcia, MD, discusses the clinical impact of the FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC.

Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

May 12th 2025

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

Allogeneic CAR T-Cell Therapy CT0596 Yields Preliminary Efficacy and Safety in R/R Myeloma

May 12th 2025

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

Avutometinib/Defactinib Expands Treatment Options for KRAS-Mutant Low-Grade Serous Ovarian Cancer

May 12th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

ADRX-0706 Secures FDA Fast Track Designation for Advanced Squamous Cell Cervical Cancer

May 12th 2025

The FDA granted fast track designation to ADRX-0706 for locally advanced or metastatic squamous cell cervical cancer.

Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors

May 9th 2025

Neoadjuvant dostarlimab led to an 82% clinical complete response and a 92% 2-year RFS rate, supporting nonoperative management in early-stage dMMR tumors.

Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD

May 8th 2025

Dr Arbour discusses the mechanisms of action of zoldonrasib and daraxonrasib and shares early data with these agents in RAS-mutant NSCLC.

Dr Monk on the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease

May 8th 2025

FDA lifts clinical hold on tabelecleucel IND, enabling trial resumption in EBV+ PTLD following HSCT or SOT in relapsed/refractory patients.

Dr Pimenta on Novel Approaches to Evaluate Tumor Progression and Immune Evasion in Soft Tissue Sarcomas

May 7th 2025

Erica Maria Pimenta, MD, PhD, discusses the future for evaluating tumor progression and immune evasion in soft tissue sarcomas.

Dr Kruse on Long-Term Data for Adjuvant Abemaciclib Plus Endocrine Therapy in HR+/ HER2– Early Breast Cancer

May 7th 2025

Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.

Updated NCCN Guidelines Recommend Naxitamab in High-Risk Neuroblastoma

May 7th 2025

The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.

Signatera MRD Assay Displays High Sensitivity, Specificity in Sarcoma

May 7th 2025

The Signatera MRD assay was associated with high levels of sensitivity and specificity in sarcomas.

T-DXd Followed by THP Improves pCR Rate in HER2+ Early Breast Cancer

May 7th 2025

Neoadjuvant T-DXd plus THP significantly improved pCR rates in HER2+ early breast cancer.

VCN-01 Plus Chemo Improves Survival in Newly Diagnosed Metastatic Pancreatic Cancer

May 7th 2025

The addition of VCN-01 to gemcitabine and nab-paclitaxel improved survival in newly diagnosed metastatic pancreatic cancer.

Dr Shum on the Evolving Treatment Paradigm for EGFR+ NSCLC

May 6th 2025

x